P. Steiner

发表

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2009, Anticancer research.

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

O. Gratzl, A. Merlo, J. Reubi, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90 Y-Labeled

O. Gratzl, A. Merlo, J. Reubi, 1999 .

Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells

Jian Yu, Lin Zhang, P. Steiner, 2003, Cancer biology & therapy.

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

K. Alitalo, D. Hicklin, Takashi Takahashi, 2007, Cancer research.

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

S. Lowe, T. Miller, M. Soengas, 2005, Cancer research.

Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.

J. Tonra, D. Surguladze, M. Prewett, 2010, Methods in molecular biology.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers

D. Hicklin, Sheetal Patel, Y. Hadari, 2007, Molecular Cancer Therapeutics.

Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor

D. Hicklin, Y. Hadari, J. Tonra, 2007, Clinical Cancer Research.

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Peter Bohlen, Dan Lu, D. Hicklin, 2005, Molecular Cancer Therapeutics.

Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact?

R. Margreiter, C. Ensinger, T. Sauper, 2004, Anticancer research.

Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

D. Hicklin, H. Brodkin, C. Seidel-Dugan, 2022, Cancer immunology research.

Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.

D. Hicklin, G. Koelsch, H. Brodkin, 2021, Cancer treatment and research communications.

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

R. Hollingsworth, Zhan Xiao, R. Tammali, 2016, Molecular Cancer Therapeutics.

100 Inhibition of PDGFRalpha in tumor stroma with MEDI-575 enhances activity of carboplatin/paclitaxel and delays tumor regrowth in a NSCLC xenograft model

R. Baffa, S. Coats, B. Jallal, 2010 .